KYTXKyverna Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Kyverna Therapeutics, Inc. against SIC 2836 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KYTX본 종목 | $432M#9 | — | 2.6x#10 | — | — | -26.5%#9 | — | -97.4%#12 | -107.1%#3 | — | — | — |
| TECX | $556M#1 | — | 2.5x#9 | — | — | -27.9%#10 | — | -33125.9%#15 | -713.5%#5 | — | — | — |
| RGNX | $524M#2 | — | 7.3x#14 | 3.1x#2 | 104.5%#3 | 14.6%#4 | -94.6%#2 | -270.2%#14 | — | — | — | — |
| EIKN | $513M#3 | — | 1.1x#2 | — | — | — | — | 0.0%#1 | — | — | — | — |
| ZURA | $471M#5 | — | 4.6x#13 | — | — | -31.0%#12 | — | -67.6%#10 | — | — | 156.3%#2 | — |
| DNA | $447M#6 | — | 1.1x#1 | 2.6x#1 | -25.1%#7 | 42.8%#2 | -185.3%#3 | -0.1%#2 | — | — | -31.7%#8 | — |
| CABA | $439M#7 | — | 2.1x#7 | — | — | -44.9%#13 | — | -79.7%#11 | — | — | 35.2%#3 | — |
| ARTV | $435M#8 | — | 1.3x#3 | — | -100.0%#8 | -28.3%#11 | — | -24.1%#6 | — | — | 281.8%#1 | — |
| CCCC | $423M#10 | — | 1.7x#6 | 11.8x#6 | 1.0%#6 | 0.3%#5 | -320.5%#5 | -42.5%#7 | — | — | — | — |
| EDIT | $405M#11 | — | 3.9x#12 | 10.0x#4 | 25.4%#4 | 32.5%#3 | -394.9%#6 | -152.0%#13 | — | — | -0.8%#5 | — |
| GRML | $492M#4 | — | 8.5x#15 | — | — | -71.6%#14 | — | -18.2%#5 | -14.6%#2 | — | -89.4%#9 | — |
| XFOR | $360M#12 | 2.5x#1 | 2.3x#8 | 10.2x#5 | 1273.2%#2 | -111.5%#15 | -247.4%#4 | -50.9%#9 | -582.0%#4 | — | 21.6%#4 | — |
| IPSC | $359M#13 | — | 1.5x#5 | 3.3x#3 | 1556.8%#1 | 92.4%#1 | -15.8%#1 | -4.1%#3 | -9.3%#1 | — | — | — |
| PALI | $350M#14 | 3.1x#2 | 2.9x#11 | — | — | -16.2%#7 | — | -13.8%#4 | — | — | — | — |
| LXEO | $340M#15 | — | 1.4x#4 | 520.0x#8 | — | -1.7%#6 | -16706.0%#8 | -42.5%#8 | — | — | -22.9%#7 | — |
| OCGN | $338M#16 | — | — | 76.6x#7 | 8.8%#5 | -25.9%#8 | -1425.7%#7 | — | — | — | -16.9%#6 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. 이 표는 생성 중 시간이 초과되어 그룹의 일부만 포함합니다. 순위는 표시된 행 내에서만 유효하며 곧 채워집니다. Table built 2026-09-16.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice